Coronavirus company news summary – Roche receives FDA EUA for new semi-quantitative test – ams wins Federal funding in Austria to bolster pandemic control

2 December 2020 (Last Updated December 2nd, 2020 10:02)

Roche has announced that its Elecsys® Anti-SARS-CoV-2 S antibody test has recieved emergency use authorisation (EUA) from the US Food and Drug Administration (FDA). The semi-quantitative blood test will be used to measure antibody levels among individuals who have been exposed to the SARS-CoV-2 virus. This could help to guide the allocation of plasma donations from recovered Covid-19 patients to those who are seriously ill with the virus, by narrowing down those with the highest antibody levels.

GENETWORx Labs have launched a diagnostic Flu A-B/COVID-19/RSV combination test to help in the early detection of all the three separate viruses from a single sample. The US has reported exploding coronavirus cases across the country, with the government looking to fast-track testing in the upcoming days in winter.

The Austrian Federal Ministries for Transport, Innovation, Technology, and Digital and Economic Affairs has awarded funding to ams, a high-performance sensor solutions supplier, to fast-track the development of a cloud-based, highly-sensitive, Lateral Flow Test (LFT) that will help in the detection of the SARS-CoV-2 virus. Based on the pre-existing ams spectral sensor AS7341L, ams says the test will offer results in 15 minutes.

Multi Radiance Medical is looking to apply for FDA EUA, after the completion of its super pulsed laser therapy technology intended to improve the respiratory condition of critical Covid-19 patients. The trial data found that MRM’s laser therapy reduced invasive intubation time by 18% and mechanical ventilation time by 23%.